ADMA Biologics, Inc. (ADMA) is a publicly traded Healthcare sector company. As of July 5, 2026, ADMA trades at $8.95 with a market cap of $2.07B and a P/E ratio of 12.97. ADMA moved +3.95% today. Year to date, ADMA is -51.25%; over the trailing twelve months it is -50.66%. Its 52-week range spans $7.21 to $25.67. Analyst consensus is strong buy with an average price target of $19.67. Rallies surfaces ADMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ADMA Biologics, Inc. (ADMA) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ADMA moved +3.95% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $8.95 |
| Market Cap | $2.07B |
| P/E Ratio | 12.97 |
| EPS | $0.69 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.67 |
| 52-Week Low | $7.21 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $509.86M |
| Net Income | $165.35M |
| Gross Margin | 61.27% |
3 analysts cover ADMA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.67.